Search results for "chemical and pharmacologic phenomena"

showing 10 items of 616 documents

Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain

2009

Adoptive transfer of T lymphocytes transduced with a T cell receptor (TCR) to impart tumor reactivity has been reported as a potential strategy to redirect immune responses to target cancer cells (Schumacher, T.N. 2002. Nat. Rev. Immunol. 2:512-519). However, the affinity of most TCRs specific for shared tumor antigens that can be isolated is usually low. Thus, strategies to increase the affinity of TCRs or the functional avidity of TCR-transduced T cells might be therapeutically beneficial. Because glycosylation affects the flexibility, movement, and interactions of surface molecules, we tested if selectively removing conserved N-glycoslyation sites in the constant regions of TCR alpha or …

CD4-Positive T-LymphocytesModels MolecularAdoptive cell transferGlycosylationCD3ImmunologyReceptors Antigen T-Cellchemical and pharmacologic phenomenaEnzyme-Linked Immunosorbent AssayStreptamerBiologyArticleCell Line03 medical and health sciencesMice0302 clinical medicineImmune systemTetramerAntigenModelsCell Line TumorNeoplasmsReceptorsImmunology and AllergyAnimalsHumansAvidity030304 developmental biology0303 health sciencesTumorReverse Transcriptase Polymerase Chain ReactionT-cell receptorTemperatureMolecularhemic and immune systemsT-CellFlow CytometryMolecular biologyAdoptive TransferAntigenbiology.protein030215 immunologyProtein Binding
researchProduct

NFATc2 and NFATc3 transcription factors play a crucial role in suppression of CD4+ T lymphocytes by CD4+ CD25+ regulatory T cells

2005

The phenotype of NFATc2(-/-) c3(-/-) (double knockout [DKO]) mice implies a disturbed regulation of T cell responses, evidenced by massive lymphadenopathy, splenomegaly, and autoaggressive phenomena. The population of CD4(+) CD25(+) T cells from DKO mice lacks regulatory capacity, except a small subpopulation that highly expresses glucocorticoid-induced tumor necrosis factor receptor family-related gene (GITR) and CD25. However, neither wild-type nor DKO CD4(+) CD25(+) regulatory T cells (T reg cells) are able to suppress proliferation of DKO CD4(+) CD25(-) T helper cells. Therefore, combined NFATc2/c3 deficiency is compatible with the development of CD4(+) CD25(+) T reg cells but renders c…

CD4-Positive T-LymphocytesT cellImmunologyPopulationchemical and pharmacologic phenomenaReceptors Nerve Growth FactorBiologyLymphocyte ActivationReceptors Tumor Necrosis FactorInterleukin 21MiceT-Lymphocyte SubsetsGlucocorticoid-Induced TNFR-Related ProteinmedicineImmunology and AllergyCytotoxic T cellAnimalsIL-2 receptorReceptoreducationTranscription factorMice Knockouteducation.field_of_studyNFATC Transcription FactorsZAP70Brief Definitive ReportNuclear Proteinshemic and immune systemsReceptors Interleukin-2Molecular biologyCoculture TechniquesDNA-Binding Proteinsmedicine.anatomical_structureTranscription FactorsThe Journal of Experimental Medicine
researchProduct

Induction of Interleukin 10–Producing, Nonproliferating Cd4+ T Cells with Regulatory Properties by Repetitive Stimulation with Allogeneic Immature Hu…

2000

The functional properties of dendritic cells (DCs) are strictly dependent on their maturational state. To analyze the influence of the maturational state of DCs on priming and differentiation of T cells, immature CD83− and mature CD83+ human DCs were used for stimulation of naive, allogeneic CD4+ T cells. Repetitive stimulation with mature DCs resulted in a strong expansion of alloreactive T cells and the exclusive development of T helper type 1 (Th1) cells. In contrast, after repetitive stimulation with immature DCs the alloreactive T cells showed an irreversibly inhibited proliferation that could not be restored by restimulation with mature DCs or peripheral blood mononuclear cells, or by…

CD4-Positive T-LymphocytesT cellImmunologyT cell differentiationDose-Response Relationship ImmunologicImmunoglobulinschemical and pharmacologic phenomenaBiologyLymphocyte ActivationT helper type 1 cellsregulatory T cellsImmunophenotypingInterleukin 21Antigens CDmedicineImmunology and AllergyCytotoxic T cellHumansTransplantation HomologousIL-2 receptorAntigensAntigen-presenting cellInterleukin 3Membrane Glycoproteinshemic and immune systemsCell DifferentiationDendritic CellsTh1 CellsNatural killer T cellFlow CytometryCell biologyInterleukin-10medicine.anatomical_structureInterleukin 12Interleukin-2Original Articleinterleukin 10Cell DivisionThe Journal of Experimental Medicine
researchProduct

Highly focused T cell responses in latent human pulmonary Mycobacterium tuberculosis infection.

2005

Abstract The elucidation of the molecular and immunological mechanisms mediating maintenance of latency in human tuberculosis aids to develop more effective vaccines and to define biologically meaningful markers for immune protection. We analyzed granuloma-associated lymphocytes (GALs) from human lung biopsies of five patients with latent Mycobacterium tuberculosis (MTB) infection. MTB CD4+ and CD8+ T cell response was highly focused in the lung, distinct from PBL, as assessed by TCR-CDR3 spectratyping coupled with a quantitative analysis of TCR VB frequencies. GALs produced IFN-γ in response to autologous macrophages infected with MTB and to defined MTB-derived HLA-A2-presented peptides Ag…

CD4-Positive T-LymphocytesT cellReceptors Antigen T-Cell alpha-betaImmunologyAntigen presentationMolecular Sequence DataEpitopes T-Lymphocytechemical and pharmacologic phenomenaBiologyCD8-Positive T-LymphocytesEpitopeMycobacterium tuberculosisInterferon-gammaAntigenBacterial ProteinsMHC class IHLA-A2 AntigenmedicineImmunology and AllergyHumansAmino Acid SequenceTuberculosis PulmonaryAntigen PresentationAntigens BacterialGranulomaMacrophagesT-cell receptorMycobacterium tuberculosisTh1 Cellsbacterial infections and mycosesbiology.organism_classificationVirologyPeptide FragmentsClone Cellsmedicine.anatomical_structureReceptor-CD3 Complex Antigen T-CellImmunologybiology.proteinCytokinesCD8Protein BindingJournal of immunology (Baltimore, Md. : 1950)
researchProduct

Monoclonal TCR mRNA transcripts are preferentially detected in the TCR variable alpha chain in CD8(+) T-lymphocytes: implications for immunomonitorin…

1999

Clinical trials have started to implement tumor-associated antigens in the form of antigenic peptides in order to augment CD8(+) T-cell responses directed against autologous cancer cells. One of the surrogate markers for successful immunization is the characterization of T-lymphocytes reacting to the immunizing peptide as determined by CDR3-length and DNA-sequence analysis. Most of the recent studies examining ex vivo T-cell responses in patients with cancer have focussed on expression and prevalence of the TCR Beta variable region, predominantly in non-sorted T-cell populations. Here, we show that clonal T-cell receptors (TCRs), as defined by DNA-fragment analysis and DNA-sequencing, appea…

CD4-Positive T-Lymphocytesmedicine.medical_treatmentPopulationUterine Cervical Neoplasmschemical and pharmacologic phenomenaCD8-Positive T-LymphocytesBiologyLymphocytes Tumor-InfiltratingAntigenAntigens NeoplasmNeoplasmsGeneticsmedicineHumansRNA Messengereducationeducation.field_of_studyT-cell receptorCancerhemic and immune systemsGeneral MedicineImmunotherapymedicine.diseaseMolecular biologyClone CellsImmunologyMonoclonalFemaleGenes T-Cell Receptor alphaCD8Alpha chainInternational Journal of Molecular Medicine
researchProduct

A CD40/CD40L feedback loop drives the breakdown of CD8+T-cell tolerance following depletion of suppressive CD4+T cells

2014

Dendritic cells (DCs) are the key APCs not only for the priming of naive T cells, but also for the induction and maintenance of peripheral T-cell tolerance. We have recently shown that cognate interactions between Foxp3(+) Tregs and steady-state DCs are crucial to maintain the tolerogenic potential of DCs. Using DIETER mice, which allow the induction of antigen presentation selectively on DCs without altering their maturation status, we show here that breakdown of CD8(+) T-cell tolerance, which ensues after depletion of suppressive CD4(+) T cells, is driven by a positive feedback loop in which autoreactive CD8(+) T cells activate DCs via CD40. These data identify ligation of CD40 on DCs as …

CD40ImmunologyAntigen presentationPriming (immunology)Peripheral toleranceFOXP3chemical and pharmacologic phenomenahemic and immune systemsBiologyImmune toleranceImmunologybiology.proteinImmunology and AllergyCytotoxic T cellAntigen-presenting cellEuropean Journal of Immunology
researchProduct

Quantitative representation of all T cells committed to develop into cytotoxic effector cells and/or interleukin 2 activity-producing helper cells wi…

1984

A limiting dilution culture system based on stimulation with concanavalin A (Con A) has been used to study the quantitative distribution of helper and of cytotoxic precursor cells in Lyt-2-defined subpopulations of murine T cells. Virtually all of the selected Lyt-2+ and Lyt-2-T cells grow and expand to large clonal colonies within an 8-9-day culture period. Our data show that upon stimulation with Con A, 90% of the Lyt-2-T cells were capable to produce interleukin 2 (IL 2) activity. In addition, IL 2 activity is produced by 8-10% of Lyt-2+ T cells. However, at the clonal level, the average of the IL2 activity produced by Lyt-2+ T cells is about 8-fold less as compared to Lyt-2-T cells. Pre…

CD40T-LymphocytesImmunologyhemic and immune systemschemical and pharmacologic phenomenaT-Lymphocytes Helper-InducerBiologyNatural killer T cellMolecular biologyClone CellsMiceInterleukin 21ImmunologyConcanavalin AInterleukin 12biology.proteinAnimalsInterleukin-2Immunology and AllergyCytotoxic T cellFemaleIL-2 receptorAntigen-presenting cellT-Lymphocytes CytotoxicInterleukin 3European Journal of Immunology
researchProduct

Functionally Altered GPI-Anchor Negative Treg Following Alemtuzumab-Based T-Cell Depletion Are Associated with Acute Gvhd.

2012

Abstract Abstract 3059 Introduction: The monoclonal anti-CD52antibody Alemtuzumab is frequently used for T-cell depletion (TCD) in the context of allogeneic hematopoietic stem cell transplantation (HSCT) to prevent graft versus host disease (GVHD). We previously demonstrated the long term persistence of functionally impaired glycosylphosphatidylinositol (GPI)-anchor negative effector T-cells in patients receiving high dose (100mg) Alemtuzumab in combination with a dose reduced conditioning regimen (Fludarabin + Melpahlan) (Meyer, Wagner et al. BMT 2010). Despite of Alemtuzumab-mediated TCD, half of our patients developed acute GVHD. Since regulatory T cells (Treg) play a major role for cont…

CD52business.industrymedicine.medical_treatmentImmunologyFOXP3hemic and immune systemschemical and pharmacologic phenomenaContext (language use)Cell BiologyHematologyHematopoietic stem cell transplantationmedicine.diseaseBiochemistryGraft-versus-host diseaseimmune system diseasesImmunologymedicineAlemtuzumabIL-2 receptorInterleukin-7 receptorbusinessmedicine.drugBlood
researchProduct

H2-M, a facilitator of MHC class II peptide loading, and its negative modulator H2-O are differentially expressed in response to proinflammatory cyto…

2000

H2-M is a major histocompatibility complex (MHC) class II-like molecule that catalyzes peptide binding to MHC class II molecules. Recently, the H2-O heterodimer, encoded by H2-Oa and H2-Ob in the MHC class II region, has been shown to be physically associated with H2-M in B cells and to downregulate H2-M function. Examination of H2-O expression in freshly isolated mouse organs revealed that H2-Oa- and H2-Ob-specific transcripts are present in both lymphoid and nonlymphoid tissues. To evaluate the gene regulation and functional impact of H2-O on antigen presentation, we examined the effects on MHCII, invariant chain (Ii), H2-M, and H2-O gene expression of interleukin (IL)-4, IL-10, and inter…

CD74ImmunologyAntigen presentationchemical and pharmacologic phenomenaMajor histocompatibility complexInterferon-gammaMiceMHC class IGeneticsCIITAAnimalsTissue DistributionRNA MessengerAntigen PresentationHLA-D AntigensMHC class IIbiologyAntigen processingHistocompatibility Antigens Class IINuclear ProteinsMHC restrictionMolecular biologyInterleukin-10Antigens Differentiation B-LymphocyteGene Expression RegulationMice Inbred DBATrans-Activatorsbiology.proteinInterleukin-4PeptidesImmunogenetics
researchProduct

Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompati…

2002

To identify endocytic receptors that allow dendritic cells (DCs) to capture and present antigens on major histocompatibility complex (MHC) class I products in vivo, we evaluated DEC-205, which is abundant on DCs in lymphoid tissues. Ovalbumin (OVA) protein, when chemically coupled to monoclonal alphaDEC-205 antibody, was presented by CD11c+ lymph node DCs, but not by CD11c- cells, to OVA-specific, CD4+ and CD8+ T cells. Receptor-mediated presentation was at least 400 times more efficient than unconjugated OVA and, for MHC class I, the DCs had to express transporter of antigenic peptides (TAP) transporters. When alphaDEC-205:OVA was injected subcutaneously, OVA protein was identified over a …

CD8-Positive T-LymphocytesMice0302 clinical medicineImmunology and AllergyCytotoxic T cellMice KnockoutAntigen Presentation0303 health sciencesMembrane GlycoproteinstoleranceAntibodies MonoclonalDEC-205 receptorrespiratory systemFlow CytometryEndocytosismedicine.anatomical_structureMHC class IFemaleOvalbuminT cellImmunologyAntigen presentationReceptors Cell Surfacechemical and pharmacologic phenomenaBiologyMajor histocompatibility complexArticleMinor Histocompatibility Antigens03 medical and health sciencesAntigenAntigens CDMHC class IImmune TolerancemedicineAnimalsLectins C-Typedendritic cellsAntigensCD40 Antigens030304 developmental biologyHistocompatibility Antigens Class IDendritic cellMolecular biologyCD11c AntigenMice Inbred C57BLCD8 T cellbiology.proteinLymph NodesCarrier ProteinsCD8030215 immunologyJournal of Experimental Medicine
researchProduct